Citigroup
ALXN

Citigroup’s Alexion Pharmaceuticals ALXN Stock Holding History

Citigroup’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24,000
Closed -$4.41M – 6554
2021
Q2 		$4.41M Hold
24,000
– – ﹤0.01% 2011
2021
Q1 		$3.67M Sell
24,000
-52,100
-68% -$8.06M ﹤0.01% 2039
2020
Q4 		$11.9M Sell
76,100
-4,600
-6% -$591K 0.01% 1411
2020
Q3 		$9.23M Sell
80,700
-79,800
-50% -$8.61M 0.01% 1426
2020
Q2 		$18M Sell
160,500
-12,300
-7% -$1.31M 0.01% 881
2020
Q1 		$15.5M Buy
172,800
+91,100
+112% +$8.94M 0.01% 881
2019
Q4 		$8.84M Sell
81,700
-44,700
-35% -$4.78M 0.01% 1590
2019
Q3 		$12.4M Buy
126,400
+53,000
+72% +$5.97M 0.01% 1244
2019
Q2 		$9.61M Buy
73,400
+36,900
+101% +$4.76M 0.01% 1419
2019
Q1 		$4.93M Sell
36,500
-66,800
-65% -$8.31M ﹤0.01% 1801
2018
Q4 		$10.1M Buy
103,300
+39,800
+63% +$4.7M 0.01% 1252
2018
Q3 		$8.83M Buy
63,500
+17,800
+39% +$2.23M 0.01% 1372
2018
Q2 		$5.67M Sell
45,700
-42,100
-48% -$4.92M 0.01% 1714
2018
Q1 		$9.79M Buy
87,800
+36,000
+69% +$4.3M 0.01% 1254
2017
Q4 		$6.2M Buy
51,800
+8,300
+19% +$1.01M 0.01% 1640
2017
Q3 		$6.1M Sell
43,500
-115,700
-73% -$15.7M 0.01% 1580
2017
Q2 		$19.4M Buy
159,200
+97,200
+157% +$11.3M 0.02% 767
2017
Q1 		$7.52M Sell
62,000
-2,800
-4% -$361K 0.01% 1345
2016
Q4 		$7.93M Buy
64,800
+47,100
+266% +$5.76M 0.01% 1373
2016
Q3 		$2.17M Sell
17,700
-21,300
-55% -$2.74M ﹤0.01% 2440
2016
Q2 		$4.55M Sell
39,000
-4,400
-10% -$624K ﹤0.01% 1651
2016
Q1 		$6.04M Buy
43,400
+24,800
+133% +$3.64M 0.01% 1392
2015
Q4 		$3.55M Sell
18,600
-3,100
-14% -$542K ﹤0.01% 2010
2015
Q3 		$3.39M Buy
21,700
+7,100
+49% +$1.3M ﹤0.01% 2004
2015
Q2 		$2.64M Buy
14,600
+6,200
+74% +$1.07M ﹤0.01% 2281
2015
Q1 		$1.46M Buy
+8,400
New +$1.52M ﹤0.01% 2751
2013
Q3 		– Sell
-13,400
Closed -$1.24M – 7069
2013
Q2 		$1.24M Buy
+13,400
New +$1.29M ﹤0.01% 2722

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Citigroup's ALXN Position: Q3 2021 in Review

Citigroup sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,404,598 shares — an estimated $809M sold.

Citigroup first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $809M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Citigroup reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Citigroup sold 4,404,598 Alexion Pharmaceuticals shares in Q3 2021, an estimated $809M.
  • Citigroup first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Citigroup's Alexion Pharmaceuticals position peaked at $809M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Citigroup's 13F filing for Q3 2021, filed 10 Nov 2021.